Related Experiment Videos

Use of bortezomib in B-cell non-Hodgkin's lymphoma

Michael Wang1, Yuhong Zhou, Liang Zhang

  • 1The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030-4009, USA. miwang@mdanderson.org

Expert Review of Anticancer Therapy
|July 13, 2006
PubMed

Insights

Bortezomib, a proteasome inhibitor, shows promising activity and tolerability in clinical trials for B-cell non-Hodgkin's lymphoma. Mantle cell lymphoma demonstrated particular sensitivity, suggesting broad potential for this cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The ubiquitin-proteasome pathway is crucial for regulating proteins involved in cell cycle and tumor growth.
  • Bortezomib (PS-341) is a potent inhibitor of this pathway.
  • Preclinical studies indicated bortezomib's efficacy against B-cell malignancies through apoptosis induction and sensitization to other therapies.

Purpose of the Study:

  • To evaluate the clinical activity and tolerability of bortezomib in patients with B-cell non-Hodgkin's lymphoma.
  • To determine the differential sensitivity of various non-Hodgkin's lymphoma subtypes to bortezomib.

Main Methods:

  • Clinical trials were conducted to assess bortezomib's safety and efficacy.
  • Patient responses and toxicities were monitored.
  • Comparative analysis of bortezomib sensitivity across different lymphoma subtypes was performed.

Main Results:

  • Bortezomib was generally well tolerated with manageable side effects in clinical trials.
  • Promising clinical activity was observed in patients with B-cell non-Hodgkin's lymphoma.
  • Mantle cell lymphoma exhibited significantly higher sensitivity to bortezomib compared to other non-Hodgkin's lymphoma subtypes.

Conclusions:

  • Bortezomib demonstrates a favorable safety profile and clinical activity in B-cell non-Hodgkin's lymphoma.
  • The drug shows particular promise for treating mantle cell lymphoma.
  • Bortezomib holds significant potential for broader application in B-cell non-Hodgkin's lymphoma treatment.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...